[logo] HealthTree Foundation
search person

Clinical Trial: Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Posted: Sep 01, 2017
Clinical Trial: Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma image

A phase II trial is open at the Fred Hutchinson Cancer Research Center in Seattle, WA to test how well the triple combination of panobinostat, carfilzomib and dexamethasone work in treating patients with multiple myeloma that has come back or does not respond to treatment. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients' blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.

What treatments are used in this trial?
- Carfilzomib ( Proteasome Inhibitor ) 
- Dexamethasone ( Steroid ) 
- Panobinostat ( Histone Deacetylase (HDAC) Inhibitor )

To learn more about this trial and sign up to receive notifications, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial To find all eligible clinical trials, click here: Study of the CD38 Antibody Daratumumab Clinical Trial

A phase II trial is open at the Fred Hutchinson Cancer Research Center in Seattle, WA to test how well the triple combination of panobinostat, carfilzomib and dexamethasone work in treating patients with multiple myeloma that has come back or does not respond to treatment. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients' blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.

What treatments are used in this trial?
- Carfilzomib ( Proteasome Inhibitor ) 
- Dexamethasone ( Steroid ) 
- Panobinostat ( Histone Deacetylase (HDAC) Inhibitor )

To learn more about this trial and sign up to receive notifications, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial To find all eligible clinical trials, click here: Study of the CD38 Antibody Daratumumab Clinical Trial
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.